Latest / Practice Point®: Pulmonology
Episode 15 - WHAT’S NEW DOC? End-of-the-Year Updates on Idiopathic Pulmonary Fibrosis
New analyses show rising prevalence of progressive pulmonary fibrosis, persistent diagnostic delays, and continued gaps in antifibrotic use. Fresh data from major trials, including nerandomilast, inhaled treprostinil, admilparant, deupirfenidone, and nalbuphine ER for chronic cough, point to meaningful advances on the horizon. At the same time, patient-centered research highlights the need for clearer communication, coordinated care, and earlier intervention to improve daily functioning and long-term outcomes.
This CME activity brings all these findings together in one clear, concise program…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.